ARTICLE | Distillery Therapeutics
Infectious disease
August 16, 2018 4:12 PM UTC
In vitro, cell culture, rat and dog studies identified a CYPA inhibitor that could help treat HCV. Chemical synthesis of analogs of the natural product sanglifehrin A and in vitro binding assays yielded a compound that bound CYPA with a Kd of 5 nM. In human hepatocyte-based replicon assays, the compound inhibited replication of an HCV genotype 2a strain with an EC50 of 98 nM. In rats and dogs, the compound had 100% and 55% oral bioavailability, and half-lives of 24 and 25 hours, respectively. Next steps by Gilead Sciences Inc. could include testing the compound in animal models of HCV...
BCIQ Company Profiles
BCIQ Target Profiles